| Heading: |
Knee Replacements |
| Question ID: |
1822733 |
| UIN: |
67337 |
| House: |
Commons |
| Date tabled: |
2025-07-14 |
| Asking Member ID: |
4124 |
| Asking Member display name: |
Dame Chi Onwurah
|
| Asking Member handle: |
ChiOnwurah
|
| Asking Member Twitter reference: |
@ChiOnwurah
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential (a) financial and (b) clinical impact of the Zimmer Biomet NexGen Legacy Posterior Stabilized (LPS) knee replacement system on the NHS. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-08-08 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Medicines and Healthcare products Regulatory Agency (MHRA) issued a field safety notice (FSN) in December 2022 about some devices in the NexGen family of knee implants. The FSN was issued following notification by the National Joint Registry (NJR) Imp... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |